Latest: FDA Approves New Biosimilar for Oncology Treatment

Atopic Dermatitis Skin Clearance Maintained Over 3 Years With Lebrikizumab

29 August, 2025

0 Mins

Lebrikizumab shows sustained efficacy and safety in managing moderate to severe atopic dermatitis over 3 years, reducing the need for rescue therapies.

Tags:

Author

American Journal Managed Care

Ciprofloxacin is non-inferior to aminoglycoside-ciprofloxacin for bubonic plague treatment

Beyond the Algorithm: Why Data Infrastructure is the Key to Successful AI in Healthcare

📢

300x250 Banner

Atopic Dermatitis Skin Clearance Maintained Over 3 Years With Lebrikizumab

Tags:

American Journal Managed Care

Ciprofloxacin is non-inferior to aminoglycoside-ciprofloxacin for bubonic plague treatment

Beyond the Algorithm: Why Data Infrastructure is the Key to Successful AI in Healthcare

Recent Content

COPD Biologics: Early Treatment Insights

Antihypertensive Medication Guidelines

Juvenile Arthritis Care Transition